Airsculpt Technologies, Inc.

AirSculpt Technologies, Inc. operates within the large and growing market for body fat reduction procedures, which includes surgical procedures like liposuction and abdominoplasty, as well as non-surgical methods such as cryolipolysis, ultrasound, and laser lipolysis. An independent third-party consultant estimated the addressable market for liposuction, body sculpting, fat transfer fillers, and skin tightening procedures to be $11 billion in 2022, with an expected compound annual growth rate of 9% through 2027 ¹. The company notes that the increased market acceptance and availability of weight-loss drugs have changed the market, potentially leading to increased demand for body contouring and skin tightening procedures.

The company's core business model revolves around its proprietary and patented AirSculpt® method, a minimally invasive body contouring treatment. This procedure removes fat and tightens skin without needles, scalpels, stitches, or general anesthesia, aiming for quick healing and precise results. Revenue is generated from these procedures, with the company operating on a 100% self-pay model, not accepting payments from government healthcare programs or third-party payers. Patients can secure third-party financing options, and the company recognizes revenue based on the expected transaction price, reduced for financing fees. Payments are typically required in advance of the service. The company operates as a holding company, with all operations conducted through Professional Associations (PAs) owned by surgeons, to which AirSculpt provides exclusive administrative, management, and business support services through Management Service Agreements (MSAs).

AirSculpt offers a broad range of fat removal procedures across various treatment areas. Key innovative fat transfer procedures include the Power BBL®, a Brazilian butt lift; the Up a Cup™, a breast enhancement procedure using the patient's own fat cells; and the Hip Flip™, an hourglass contouring procedure. In fiscal year 2022, the company introduced AirSculpt®+, which combines fat removal with technology for instant skin tightening using helium gas and radiofrequency energy, and AirSculpt® Smooth, an FDA-cleared cellulite reduction treatment for the buttocks and thighs. The company's patent portfolio as of December 31, 2025, includes two issued U.S. utility patents, one pending U.S. utility patent application, one pending U.S. provisional patent application, one pending U.S. design patent application, one pending Canada utility patent application, and one pending U.K. utility patent application ².

For the fiscal year ended December 31, 2025, AirSculpt reported total revenue of $151.818 million ³, a decrease from $180.350 million ⁴ in 2024. The cost of service was $61.690 million ⁵, representing 40.6% of revenue ⁶. Selling, general and administrative expenses totaled $82.180 million ⁷, or 54.1% of revenue ⁸. The company incurred a loss from operations of $(11.560) million ⁹ and a net loss of $(11.667) million ¹⁰. Basic and diluted loss per share were both $(0.19) ¹¹. Adjusted EBITDA was $15.097 million ¹², with an Adjusted EBITDA Margin of 9.9% ¹³. Cash and cash equivalents stood at $8.449 million ¹⁴ as of December 31, 2025, and total outstanding indebtedness under its senior credit facility was approximately $75.8 million ¹⁵, consisting of $56.0 million ¹⁶ in term loans and $5.0 million ¹⁷ available on its revolving credit facility.

Comparing 2025 to 2024, revenue decreased by $28.5 million, or 15.8% ¹⁸, primarily due to lower case volume, partially offset by an increased rate. Cases performed declined from 14,036 ¹⁹ in 2024 to 11,852 ²⁰ in 2025, a 15.6% decrease ²¹. Revenue per case slightly decreased by 0.3% ²² to $12,809 ²³ in 2025 from $12,849 ²⁴ in 2024. Cost of service decreased by $9.5 million, or 13.3% ²⁵, but increased as a percentage of revenue from 39.5% ²⁶ to 40.6% ²⁷ due to the revenue decline and inability to leverage fixed costs. Selling, general and administrative expenses decreased by $16.7 million, or 16.9% ²⁸, driven by a $5.6 million ²⁹ decrease in advertising costs, a $1.4 million ³⁰ reduction in payroll, a $3.7 million ³¹ decrease in severance expense, a $1.6 million ³² decrease in professional services, a $1.3 million ³³ reduction in travel expense, and a $1.4 million ³⁴ reduction in stock compensation expense. Customer acquisition costs increased from $2,950 ³⁵ per customer in 2024 to $3,114 ³⁶ in 2025. Net loss widened from $(8.018) million ³⁷ in 2024 to $(11.667) million ³⁸ in 2025.

During fiscal year 2025, the company recorded a $4.5 million ³⁹ loss related to the impairment of a portion of its Salesforce implementation project and $2.152 million ⁴⁰ in costs related to the closure of its London facility. The London facility closure included a $2.4 million ⁴¹ loss on property, plant, and equipment, $3.3 million ⁴² in rent expense from accelerated amortization, offset by a $3.2 million ⁴³ gain on deconsolidation related to net liabilities, and $0.3 million ⁴⁴ income from reclassification of cumulative translation adjustment. The company also completed an underwritten public offering on June 11, 2025, selling 3,634,000 shares ⁴⁵ for net proceeds of approximately $13.8 million ⁴⁶, which were used to prepay a portion of outstanding indebtedness and for general corporate purposes. Additionally, an at-the-market offering program was commenced on March 14, 2025, under which approximately 2.1 million shares ⁴⁷ were sold for total net proceeds of approximately $5.6 million ⁴⁸ during 2025.

AirSculpt is focused on returning to revenue growth through several strategic and growth initiatives. These include optimizing marketing investment by focusing on proven techniques and exploring new areas like online video and social marketing channels under the direction of its Chief Digital Officer. The company also aims to improve its go-to-market and sales strategies under its Chief Sales Officer, with enhanced training, improved sales processes, and a greater focus on lead conversion.

A key growth area involves expanding consumer financing offerings to enhance affordability, increase customer accessibility, and drive sales growth. By providing flexible payment solutions, the company intends to attract a broader customer base, improve conversion rates, and strengthen customer loyalty. Another significant growth vector is new product innovation, particularly in skin tightening, which is expected to expand customer reach and generate incremental revenues. The company is expanding its pilot program for skin tightening as a standalone offering and continues to develop and introduce new procedures like the Hip Flip® and CankCure® to meet patient demand and increase center utilization.

Regarding operational outlook, the company implemented a cost reduction program in fiscal year 2025, estimated to eliminate approximately $3.0 million ⁴⁹ in annual overhead costs and contracted expenses. The company also paused de novo center and new procedure room openings in the near term due to initiatives to improve liquidity. While new center openings are not expected in the near term, expanding the North American footprint remains a part of the long-term growth strategy, with over 200 potential locations identified in the U.S. and Canada. The company plans to continue to assess the design and maintenance of formal accounting policies, procedures, and controls to achieve complete, accurate, and timely financial accounting, reporting, and disclosures, including controls over the preparation and review of account reconciliations.

Planned capital allocation includes continued investment in information technology and infrastructure, including the corporate office. The company's term loan and revolving credit facility mature on May 11, 2027 ⁵⁰, and these obligations will need to be restructured or paid out of available cash. The company believes that cash expected to be generated from operations will be sufficient for working capital requirements, liquidity obligations, and payments due under existing credit facilities for at least the next 12 months. As of December 31, 2025, the company had $8.4 million ⁵¹ in cash and cash equivalents and $5.0 million ⁵² available under its revolving credit facility. Subsequent to December 31, 2025, the company voluntarily prepaid $10.0 million ⁵³ of the principal balance of the term loans using cash on hand and sold an additional approximate 5.9 million shares ⁵⁴ of common stock through its at-the-market offering program for total net proceeds of approximately $14.8 million ⁵⁵.

Management explicitly flagged several structural headwinds and execution risks. The increased market acceptance, availability, and customer awareness of weight-loss drugs have changed the market for body fat reduction procedures, and it is difficult to predict the long-term outlook of this market, including the efficacy and potential drawbacks of these drugs. The company cannot be certain of the impact these weight-loss drugs will have on the market for body fat reduction procedures. The company also faces competition for surgeons and other workers, with the supply of this labor force being finite. If the company cannot hire adequate staff, it will not be able to operate effectively or open new centers.

AirSculpt faces material risks including macroeconomic trends such as inflation and rising interest rates, which could adversely affect operating expenses and debt service costs. Geopolitical instability, including ongoing military conflicts and tensions between major global powers, could disrupt the global economy, supply chains, and increase costs. The company is highly dependent on the market acceptance of its AirSculpt® procedure, and insufficient patient demand or negative publicity could harm financial results. Competition in the body contouring market is intense, and the emergence of safer, more effective, or less expensive solutions, including weight-loss drugs, could reduce commercial opportunities. The company relies on a single third-party manufacturer, Euromi, for key handpiece components, making it vulnerable to supply interruptions or price fluctuations. Compliance with numerous federal and state laws and regulations, particularly those related to the corporate practice of medicine and fee-splitting, is critical, and changes or adverse interpretations could lead to significant penalties or require costly operational changes. The company's variable rate debt exposes it to interest rate risk, with a 100 basis point increase or decrease in market interest rates potentially changing interest expense by approximately $0.6 million ⁵⁶ over a twelve-month period. Furthermore, the company identified a material weakness in internal controls over financial reporting related to general accounting and financial reporting processes, and specifically the accounting for leases, which required revision of previously issued financial statements.

Management's overall tone emphasizes a strategic pivot towards restoring revenue growth and improving operational efficiency in response to recent declines. Key forward-looking statements include the focus on optimizing marketing investment, strengthening the consultative sales model, and expanding consumer financing options to drive sales growth. Management also highlights a commitment to new product innovation, particularly in skin tightening, to broaden customer reach and generate incremental revenues. While new center openings are paused in the near term to improve liquidity, management views North American expansion as a long-term growth strategy, identifying over 200 potential locations in the U.S. and Canada. The company is actively implementing remediation measures to address identified material weaknesses in internal controls over financial reporting, including enhancing controls over lease accounting, improving documentation, and engaging external accounting advisors.